AR and prostate cancer: Studies show that CDK7 inhibition can transiently block the functional activity and expression of the oncogenic drivers (AR, ETS, MYC, and E2F) in prostate cancer, and all these changes require the involvement of MED1 as a cofactor47,54–56.